Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3

HOUSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it will host an analyst and investor luncheon event and webcast on Monday, December 3, 2018 at 12:00 p.m.1:30 p.m. PST in San Diego, California.

The event will follow the Company’s key data presentations at the 60thAmerican Society of Hematology (ASH) Annual Meeting, including interim analyses of the overall results from the BP-004 trial in children with acute leukemias and nonmalignant blood diseases, as well as the comparator C-004 trial, a multicenter, observational study of similar pediatric patients receiving a matched unrelated donor (MUD) transplant. Featured speakers include Dr. Alice Bertaina, Associate Professor of Pediatrics (Stem Cell Transplantation), Lucile Packard Children’s Hospital at the Stanford School of Medicine, as well as Bellicum senior management.

A webcast replay of the event will be available on the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-celTM, is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.​

Source: Bellicum Pharmaceuticals

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@soleburytrout.com

Bellicum Logo.jpg

Source: Bellicum Pharmaceuticals, Inc.